Vaso-Occlusive Crisis clinical trials at UCSF
3 in progress, 1 open to eligible people
Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
open to eligible people ages 12 years and up
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
Oakland, California and other locations
Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Sorry, in progress, not accepting new patients
This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD). Participants will be randomized to receive either inclacumab or placebo.
Oakland, California and other locations
Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Sorry, in progress, not accepting new patients
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.
Oakland, California and other locations
Last updated: